JNJ vs JUNS · P/E 17, rev $49.37B vs rev $21.8K
Johnson & Johnson (JNJ) versus Jupiter Neurosciences, Inc. Common Stock (JUNS) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Jupiter Neurosciences, Inc. Common Stock (JUNS) is a biotechnology company listed on NASDAQ.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported JUNS revenue for 2025-12-31 was $21.8K. Net income was -$8.6M. JUNS currently screens at market cap $10.0M.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. JUNS currently screens at market cap $10.0M.
Not investment advice. Open the JNJ and JUNS stock pages for the full models.
Not investment advice.